Sequence analysis of travel-related SARS-CoV-2 cases in the Greater Geelong 1 2 region, Australia 3 Tarka Raj Bhatta 1,2,#, Anthony Chamings 1,2,#, Kwee-Chin Liew 3, Freya Langham 4, 4 Rudi Gasser ⁴, Owen Harris ³, Andrew Gador-Whyte ⁴, John Stenos ^{4,5}, Eugene Athan ^{2,4}, 5 and Soren Alexandersen 1,2,4,* 6 7 ¹ Geelong Centre for Emerging Infectious Diseases, Geelong, VIC 3220, Australia; ² Deakin University, 8 Geelong, VIC 3220, Australia; ³ Australian Clinical Labs, Geelong, VIC 3220; ⁴ Barwon Health, University 9 Hospital Geelong, Geelong, VIC 3220 Australia; ⁵ Australian Rickettsial Reference Laboratory, Geelong, 10 VIC 3220, Australia 11 12 # These co-authors contributed equally 13 *Corresponding Author: soren.alexandersen@deakin.edu.au; Tel.: +61 (0) 342159635 (S.A) 14

Abstract

- 2 This study reports the sequence analysis of severe acute respiratory syndrome coronavirus-2
- 3 (SARS-CoV-2) from infected individuals within the Greater Geelong region, Victoria,
- 4 Australia. All but one individual had recently returned from travelling abroad, and all had
- 5 clinical signs consistent with SARS-CoV-2 infection. SARS-CoV-2 belonging to three
- 6 lineages were detected and represent separate introductions of the virus into the region.
- 7 Sequence data were consistent with the recent travel history of each case. Full virus genome
- 8 sequencing can play an important role in supporting local epidemiological tracing and
- 9 monitoring for community transmission. Quality of the SARS-CoV-2 sequences obtained was
- 10 highly dependent on appropriate sample collection and handling.

Introduction

1

2

3

4 5

6

7 8

9

1011

12 13

14

15

16

17

18

19

20

2122

23

24

In late December 2019 a novel betacoronavirus, subsequently named severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), first appeared in Wuhan, Hubei Province, China ^{1,2}. The virus could be readily transmitted from human to human by respiratory droplets and rapidly spread worldwide ^{3,4}. On 25th January 2020, the Australian Department of Health reported the first confirmed case of SARS-CoV-2 infection in Melbourne, Australia in a man returning to Australia from Wuhan on the 19th of January 2020 ⁵. On the 7th of March 2020, the city of Greater Geelong, the second largest population centre in the Australian state of Victoria, confirmed its first case of SARS-CoV-2 infection, the 20th in Victoria, in a traveller returning from the USA 6. On the 11th of March 2020, when more than 118,000 cases from 114 countries around the world had been reported, the World Health Organization (WHO) declared SARS-CoV-2 infection a global pandemic ^{7,8}. Between the 15th and 16th of March 2020, Australia implemented travel restrictions including banning non-residents from entering the country and for all returning resident travellers to self-isolate for 2 weeks, as well as domestic movement restrictions and social distancing measures including closing of social venues and restriction or limit on the number of people gathering in one location 9,10 . The regional health network in the Greater Geelong region commenced SARS-CoV-2 sample collection and testing in the last week of January 2020. In addition to the state reference laboratory, local laboratories mobilised to setup diagnostic PCR capacity. We describe here next generation sequencing (NGS) and analysis of SARS-CoV-2 sequences from SARS-CoV-2 positive samples collected from 7th March to the 14th of April 2020 to understand the molecular epidemiology of the outbreak in the Greater Geelong region. We briefly describe how sequence analysis can support local epidemiological investigations. We also show how proper sample collection and handling influence overall sequence quality.

Results

1

2

Virus sequencing of SARS-CoV-2 positive samples

3 Ampliseq NGS for SARS-CoV-2 was attempted on the 13 positive samples and the one 4 negative sample as a control (Table 1). All samples were taken through the Ampliseq process, 5 however, two samples (GC-17 and GC-22, Table 1) failed to amplify sufficiently during the 6 Amplised panel PCR and were not processed further. These were also the highest Ct samples 7 for which sequencing was attempted with Ct values of 33 and 34 respectively. The remaining 8 11 positive samples (from 7 individuals) and 1 negative sample (GC-28, Table 1) were 9 sequenced and generated a total of approximately 54 million reads with an average of 4.9 10 million reads per sample (1.1 million - 14.3 million). The negative sample was confirmed 11 negative for SARS-CoV-2 reads by NGS. The coverage and quality of the obtained reads of 12 the 11 positive samples varied and correlated somewhat with the virus load as estimated by 13 the RT-PCR, except for one sample (GC-25, Table 1) which despite a high virus load 14 generated short reads and poorer sequence. Overall, we were able to assemble near full length 15 SARS-CoV-2 genome consensus sequences of 6 samples (designated VIC-CBA1 to VIC-16 CBA6, Table 1) while 5 samples (GC-12, GC-20, GC-21, GC-25 and GC-51, Table 1) only 17 generated partial virus coverage although, except for GC-25, having reads of high quality. 18 The near complete genomes came from samples with a RT-PCR Ct of 31 or lower, while the 19 sequences with partial coverage, except for GC-25, all came from samples with a Ct of 31 or 20 higher. 21 The six near full length sequences, VIC-CBA1 to VIC-CBA6, were deposited in GISAID 22 under accession numbers EPI ISL 420855, EPI ISL 420876, EPI ISL 420877 and 23 EPI_ISL_430064 to EPI_ISL_430066 and were obtained from swabs taken from four 24 individuals. Two individuals had two separate swabs taken 11-15 days apart which generated 25 near complete sequence. Interestingly, for one of these multiple sampled individuals from 26 which two near complete virus genomes were obtained (GC-11 and GC-24, Table 1), another 27 two intervening samples produced only partial sequence (GC-20) or did not amplify in the 28 Ampliseq PCR (GC-22) (Table 1). For the other individual for which multiple samples were 29 sequenced, GC-14 and GC-23 sampled 11 days apart, contributed good sequences while a 30 later sample (GC-51, Table 1) obtained 17 days after the first sample (GC-14), only provided 31 partial sequence (Table 1). In total 6 near full length SARS-CoV-2 sequences were obtained 32 and used for further analysis.

Phylogenetic and Network analysis

1

2

3

4

5

6

7

8

9

10

11 12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

The 6 near full length consensus sequences of SARS-CoV-2 were compared to related sequences available in GISAID as of April 23, 2020. Fourteen representative closely related sequences, as well as the two earliest SARS-CoV-2 virus sequences from Wuhan, China (WH01_12_26; GISAID accession number EPI_ISL_406798 and WH04_01_05; GISAID accession number EPI ISL 406801) were included in this analysis (Table S1). A neighbourjoining tree was generated based on nucleotide differences and rooted on the WH01 12 26 sequence as the earliest virus sequence available (Figure 1, for details of abbreviated sequence names see Table S1). The same sequences were analysed by maximum parsimony network analysis ^{11,12} and arranged by date of sampling (Figure 2). The first SARS-CoV2 positive sample from Greater Geelong (sampled on 7th March 2020), designated CBA4_03_07, clustered together with sequences reported from the USA (UW3895_03_27; shown as a representative sequence) and other sequences from Victoria (VIC08 03 15) in both analyses. Interestingly, this individual had returned from travelling in the USA (Table 1). This sequence belonged to a lineage more similar to WH04 01 05 than WH01 12 26 and has been designated as lineage A.1 in Pangolin COVID-19 Lineage Assigner 13 (https://pangolin.cog-uk.io/) (Figure 1 and 2). The other near full length virus sequences belonged to lineages more related to the WH01_12_26 virus, but which have a characteristic aspartic acid to glycine (D-G) amino acid substitution within the spike glycoprotein (S) region caused by a change in one nucleotide at position 23403 (Table 2). The second individual with full length sequence of SARS-CoV-2, designated CBA1 03 23, was closely related to virus sequences obtained around the same time from Victoria (VIC311 03 23), the USA (UW213 03 13) and Europe (Figure 1 and 2). This individual had recently returned to Australia from Europe (Table 1). Sequences CBA3_03_28 and CBA5_04_08, from the third individual but sampled 11 days apart and who also had recently returned from the UK, were closely related to CBA1_03_23 (only 2 nucleotide difference) and to virus sequences from Victoria (VIC52_03_12) (Figure 1-2). These three sequences, CBA1_03_23, CBA3_03_28 and CBA5_04_08 were more closely related to WH01_12_26 and belonged to the lineage B.1, with the characteristic 3-nucleotides substitution (GGG to AAC) at nucleotides 28881-28883 (Figure 1-2 and Table 2) in the nucleocapsid phosphoprotein (N protein) gene. These changes result in a 2 amino acid change from arginine-glycine (RG) to lysine-arginine (KR) (Table 2), and therefore a gain of an additional basic amino acid in this part of the N protein. CBA2_03_24 and CBA6_04_07, from the fourth individual sampled 14 days apart, generated identical sequences and were relatively closely related to virus

sequences from England (Engl295_03_25) and Victoria (VIC196_03_19) belonging to lineage B.1.13 ¹³ (Figure 1-2). This individual reported recently returning from the UK and

was tested after developing symptoms of mild upper respiratory tract infection (Table 1).

Interestingly, although sequences CBA3_03_28 and CBA5_04_08 were from samples obtained from the same individual taken 11 days apart, the later sequence, CBA5_04_08, appeared to have an additional change at nucleotide 29066 in the N protein resulting in an amino acid change from a threonine to an alanine (T-A) (see Table 2 and detailed section on amino acid changes below). A third sample (GC-51, Table 1) was obtained from this individual six days after the second sample, and seventeen days after the initial sample was collected, however only partial sequence was obtained. This partial sequence also had the AAC sequence at nucleotides 28881-28883 characteristic for this lineage, although no reads were obtained for the region at nucleotide 29066 where CBA3_03_28 and CBA5_04_08 differed (Figure 2). The sequence data from GC-51 also identified a deletion at nucleotide 15951 changing the reading frame and immediately running into a stop codon at position 15953-15955 (TAG). In addition, this sample, GC-51, also had a nucleotide change at nucleotide position 16000 (C to T), both differences not seen in any other of our sequences.

Amino acid polymorphisms in our SARS-CoV-2 sequences

Comparison of the obtained six near full length SARS-CoV-2 sequences revealed changes at 23 nucleotide positions of which 13 changed amino acid when compared with the WH01_12_26 sequence (Table 2). While these sequences overall had 6 nucleotide changes in the ORF1a region, none of these changed the amino acid sequence. In contrast, 4 out of 5 nucleotide changes in the ORF1b (nsp12, 13 and 15) region changed amino acids (Table 2). Similarly, 2 out of 3 nucleotide changes resulted in amino acid changes in the surface glycoprotein (S) region including one mentioned above at nucleotide 23403, while each single nucleotide changes in ORF3a, ORF7a and ORF8 regions, resulted in amino acid changes in their respective proteins. The 3 nucleotides at 28881-28883 affects two codons and results in a change in two amino acids while a third change at 29066 also change the corresponding amino acid in the N protein (Table 2).

Discussion

1

2 In this study we describe the use of NGS to complement the epidemiological and clinical 3 investigation of SARS-CoV-2 infections detected in the Greater Geelong region, Victoria, 4 Australia during the period from the first local case on 7th March until 14th April 2020. 5 Phylogenetic and network analysis of 6 near full length sequences of SARS-CoV-2 indicated 6 at least three or more separate introductions of the virus into the region. All cases were 7 initially symptomatic and with a history of recent travel or working in health care, prompting 8 their testing. The earliest introduction of SARS-CoV-2 to the Greater Geelong area on 7th 9 March 2020 (CBA4 03 07, Table 1) belonged to a lineage related to WH04 01 05 (GISAID 10 accession number, EPI_ISL_406801), currently believed to be one of the phylogenetically 11 earliest SARS-CoV-2 sequences and designated as lineage A.1 in Pangolin COVID-19 12 Lineage Assigner ¹³. This lineage was commonly detected in the United States from where 13 this traveller had recently returned. The full length sequence (CBA1_03_23, Table 1) from 14 the second individual and the two full length sequences (CBA3_03_28 and CBA5_04_08, 15 Table 1) from the third individual, belonged to lineage B.1, which was commonly reported from cases in Europe and the United Kingdom ¹³. These lineages have a characteristic 3-16 17 nucleotides substitution (GGG to AAC) at nucleotides 28881-28883. These two individuals 18 had recently travelled to Europe or the United Kingdom. The two near full length sequences 19 of SARS-CoV-2 (CBA2 03 24 and CBA6 04 07) from the fourth individual belonged to lineage B.1.13 13 which was commonly detected in the United Kingdom from where the 20 21 individual had recently travelled. 22 Generally, SARS-CoV-2 positive samples with a Ct value of 31 or lower were found to 23 generate near full length sequences of SARS-CoV-2 with the Ion Torrent Ampliseq method. 24 In samples with a Ct value of 31 or higher, only partial virus genome sequences were 25 obtained. However, sample GC-25 was an exception with a Ct value of 19. Very poor 26 sequence data was obtained from this sample, and it was later determined that the swab from 27 this individual had initially been placed in sterile water as opposed to an isotonic buffer, 28 probably contributing to disruption of any coronavirus virions and degradation of the 29 genomic RNA. In addition, we observed poor virus sequencing in two samples (GC-20 30 (Ct31) and GC-22 (Ct34)) taken 24 hours apart from one individual and in a sample from other individual (GC-21, Ct 31) taken during a local shortage of high quality swabs on 2-3 31 32 April 2020. A subsequent sample (GC-24, Table 1) taken from the same individual as GC-33 20 and GC-22, but three days later and with the high quality swab type, resulted in a sample

with a Ct value of 31 and from which a near full length sequence of SARS-CoV-2 genome could be assembled (sample GC-24, sequence CBA6 04 07). Regional virus sequencing and detailed recording of sample collection and subsequent handling has been valuable to help in understanding the local epidemic, inform ongoing SARS-CoV-2 surveillance, and explain the variations in Ct and sequence data obtained from samples. Moreover, the findings are consistent with the epidemiological and case history data indicating that these were likely introductions of the virus to the area from returning travellers. To date, most of the early cases in the state of Victoria have been introductions from returning travellers ¹⁴. Ongoing virus sequencing on local RT-PCR positive samples could complement epidemiological contact tracing and be a sensitive method to detect introduction of new lineages and/or early community transmission.

Materials and Methods

Samples

1

2

3

4

5

6

7

8

9

10

11

12

1314

15

16

17

18

19

20

21

22

23

2425

26

27

28

29

30

31

32

33

Combined nasopharyngeal and oropharyngeal swab samples were collected from individuals in the region of Greater Geelong, Victoria, Australia between the 28th of January to the 14th of April 2020. Testing by real time reverse-transcription PCR (RT-PCR) occurred at either Barwon Health's Australian Rickettsial Reference Laboratory (ARRL) or at Australian Clinical Labs (ACL). Remaining sample material left over from the initial diagnostic testing was stored at -80 °C and subsequently transferred to the Geelong Centre for Emerging Infectious Diseases (GCEID) for additional RT-PCR testing and next generation sequencing (NGS). Thirteen positive samples from a total of eight individuals were identified and were included in this study. One positive individual was sampled four times and another positive individual sampled three times to monitor the progression of their infection (Table 1). Out of the 8 positive individuals, 4 were health care workers. All except one had a history of recent travel, and all had clinical symptoms consistent with SARS-CoV-2 infection (Table 1). As a negative control, we also included a SARS-CoV-2 PCR-negative swab (GC-28, Table 1). Samples were collected for this study with approval from the Barwon Health Human Research Ethics Committee (Ref HREC 20/56), and all participants gave their informed consent for their samples and case description to be included. All methods were carried out in accordance with relevant guidelines and regulations and all experimental protocols were

Nucleic acid extraction and SARS-CoV-2 RT-PCR at GCEID

approved by the Barwon Health Ethics Committee.

Nucleic acid extraction at GCEID was carried out on all thirteen SARS-CoV-2 positive swabs and one SARS-CoV-2 negative swab (Table 1). Nucleic acid was extracted from 50 μl of swab media using the MagMAXTM Viral/Pathogen Nucleic Acid Isolation Kit (Thermofisher Scientific, Victoria, Australia) and eluted into 90 μl elution solution using a KingFisher Flex extraction robot (Thermofisher Scientific) according to the manufacturer's instructions. The extracted nucleic acids were tested for SARS-CoV-2 using the TaqPathTM 1-Step Multiplex Master Mix without ROX (Thermofisher Scientific, Victoria, Australia) together with the TaqPathTM COVID-19 RT-PCR Kit (Thermofisher Scientific, Victoria, Australia) using 2.5 μL of extracted nucleic acids added to a final PCR volume of 12.5 μl according to the manufacturer's instructions. This SARS-CoV-2 RT-PCR simultaneously detected three virus targets in the ORF1ab, N Gene and S Gene, and one internal extraction control target (MS2 Phage), and was run on a QuantStudioTM Flex 6 real-time thermal cycler

- 1 (Applied BiosystemsTM) at 25 °C for 2 min, 53 °C for 10 min, 95 °C for 2 min and 40 cycles
- 2 of 95 °C for 3 sec, 60°C for 30 sec

3

cDNA Synthesis, NGS and Data analysis

4 cDNA synthesis for NGS was performed on the nucleic acids extracted from the 13 positive 5 samples and 1 negative sample by first incubating the RNA at 70°C for 5 minutes, and then rapidly cooling on ice. SuperScriptTM VILOTM Master Mix (Thermofisher Scientific, 6 Victoria, Australia) was used as per the manufacturers' instructions and described previously 7 8 ¹⁵. Obtained cDNA was then amplified using the Ion AmpliseqTM Library Kit 2.0 (Thermofisher Scientific, Victoria, Australia) 11,12 and a commercially available SARS-CoV-9 10 2 Ampliseq panel kindly provided by Thermofisher Scientific, Victoria, Australia. This 11 Ampliseq panel contained 237 amplicons covering the near full genome of SARS-CoV-2 and 12 an additional 5 amplicons targeting cellular genes in two primer pools. Amplification was 13 done following the manufacturer's instructions for either 21, 27 or 35 cycles depending on 14 the estimated virus load in the samples as determined by the multiplex RT-PCR. The Ion 15 Library TaqManTM Quantification Kit (Thermofisher Scientific, Victoria, Australia) was 16 used for library quantification, and the libraries were run on three Ion Torrent 530 chips in 17 an Ion S5 XL genetic sequencer (Thermofisher Scientific) at a concentration of 50pM as per the manufacturer's protocols and as described previously ^{15,16}. The sequence reads generated 18 19 were mapped to a SARS-CoV-2 reference genome (NCBI GenBank accession number 20 MN908947) ¹ using the TMAP software included in the Torrent Suite 5.10.1 ¹⁷, and 21 visualized in Integrative Genomic Viewer ¹⁸ (IGV 2.6.3) (Broad Institute, Cambridge, MA, USA). Near complete and partial SARS-CoV-2 genomes were aligned using Clustal-W ¹⁹ in 22 23 MEGA 7 software ²⁰. Related representative sequences from around the world were selected and downloaded on 23rd April 2020 from the Global Initiative on Sharing All influenza 24 Database (GISAID) ^{21,22} (https://www.gisaid.org/) and used for comparative phylogenetic 25 26 analysis. A phylogenetic tree was generated by using the Neighbour Joining method in 27 MEGA 7 software ²⁰. Network analysis of consensus sequences was carried out in Network v5 23 (Fluxus-Engineering, Clare, England) with an epsilon value of 10 as described 28 29 previously 11. Pangolin COVID-19 Lineage Assigner 13 (https://pangolin.cog-uk.io/) was used on 14th May 2020 to assign lineages for the SARS-CoV-2 sequences. 30

Data Availability

- All the sequences generated have been deposited in GISAID under accession numbers
- 3 EPI_ISL_420855, EPI_ISL_420876, EPI_ISL_420877 and EPI_ISL_430064 to
- 4 EPI_ISL_430066. Additional datasets analysed in the paper can be made available from the
- 5 authors upon reasonable request.

6 7

1

References

- 8
- 9 1 Wu, F. *et al.* A new coronavirus associated with human respiratory disease in China. *Nature* 579, 265-269 (2020).
- Hui, D. S. *et al.* The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health- the latest 2019 novel coronavirus outbreak in Wuhan, China. *Int. J. Infect. Dis.* **91**, 264-266 (2020).
- 14 3 Chan, J. F.-W. *et al.* A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *The Lancet* 395, 514-523 (2020).
- Dong, E., Du, H. & Gardner, L. An interactive web-based dashboard to track COVID-19 in real time. *The Lancet infectious diseases* (2020).
- 19 5 First confirmed case of novel coronavirus in Australia, 20 https://www.health.gov.au/ministers/the-hon-greg-hunt-mp/media/first-confirmed-case-of-novel-coronavirus-in-australia (2020).
- Health Alert COVID-19 (2019 Novel Coronavirus), https://westvicphn.com.au/about-us/latest-news/health-alert-2019-novel-coronavirus-ncov/ (2020).
- World Health Organization, Virtual press conference on COVID-19-11 March 2020,
 (2020).
- 28 8 Coronavirus disease 2019 (COVID-19) Situation Report 51, 29 (2020).">https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf?sfvrsn=1ba62e57_10> (2020).
- 31 9 *Update on coronavirus measures*, <<u>https://www.pm.gov.au/media/update-coronavirus-measures-24-March-2020</u>> (2020).
- 33 10 *Coronavirus measures endorsed by national cabinet*, < 34 https://www.pm.gov.au/media/coronavirus-measures-endorsed-national-cabinet (2020).
- Alexandersen, S., Nelson, T. M., Hodge, J. & Druce, J. Evolutionary and network analysis of virus sequences from infants infected with an Australian recombinant strain of human parechovirus type 3. *Sci. Rep.* **7**, 1-12 (2017).
- Chamings, A. *et al.* Evolutionary analysis of human parechovirus type 3 and clinical outcomes of infection during the 2017–18 Australian epidemic. *Sci. Rep.* **9**, 1-9 (2019).
- 40 13 Rambaut, A. *et al.* A dynamic nomenclature proposal for SARS-CoV-2 to assist genomic epidemiology. *bioRxiv* (2020).
- 42 14 *Coronavirus (COVID-19)*, https://www.dhhs.vic.gov.au/coronavirus> (2020).
- Bhatta, T. R., Chamings, A., Vibin, J. & Alexandersen, S. Detection and characterisation of canine astrovirus, canine parvovirus and canine papillomavirus in puppies using next generation sequencing. *Sci. Rep.* **9**, 1-10 (2019).
- Hatta, T. R., Chamings, A., Vibin, J., Klaassen, M. & Alexandersen, S. Detection of a Reassortant H9N2 Avian Influenza Virus with Intercontinental Gene Segments in a Resident Australian Chestnut Teal. *Viruses* 12, 88 (2020).
- 49 17 Caboche, S., Audebert, C., Lemoine, Y. & Hot, D. Comparison of mapping algorithms used

- in high-throughput sequencing: application to Ion Torrent data. *BMC Genomics* **15**, 264 (2014).
- Thorvaldsdóttir, H., Robinson, J. T. & Mesirov, J. P. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. *Briefings in bioinformatics* **14**, 178-192 (2013).
- 6 19 Larkin, M. et al. Clustal W and Clustal X version 2.0 Bioinformatics 23, 2947–2948 (2007).
- Kumar, S., Stecher, G. & Tamura, K. MEGA7: molecular evolutionary genetics analysis version 7.0 for bigger datasets. *Mol. Biol. Evol.* **33**, 1870-1874 (2016).
- 9 21 Elbe, S. & Buckland-Merrett, G. Data, disease and diplomacy: GISAID's innovative contribution to global health. *Global Challenges* **1**, 33-46 (2017).
- Shu, Y. & McCauley, J. GISAID: Global initiative on sharing all influenza data–from vision to reality. *Eurosurveillance* **22** (2017).
- Polzin, T. & Daneshmand, S. V. On Steiner trees and minimum spanning trees in hypergraphs. *Operations Research Letters* **31**, 12-20 (2003).

Acknowledgements

1

- 2 This research was funded by Deakin University, Barwon Health and CSIRO and from the
- 3 National Health and Medical Research Council (NHMRC) equipment grant number
- 4 GNT9000413 to S.A. We acknowledge ARRL and ACL and their staff for providing samples
- 5 and for doing the initial diagnostic SARS-CoV-2 testing and in particular acknowledge Dr.
- 6 Richard McCoy from ACL for his assistance in providing samples. We gratefully
- 7 acknowledge Thermofisher Scientific, Victoria, Australia, for supplying the Ampliseq panel
- 8 used in this study. We also acknowledge Jason Hodge, laboratory manager of the GCEID
- 9 laboratory for his technical input. Finally, we gratefully acknowledge the authors and
- originating and submitting laboratories for the sequences and meta-data shared through
- GISAID's EpiFluTM Database ²¹ which we have used in this study (Table S1).

Author Contributions

- 13 S.A. initiated the study and coordinated all work carried out at GCEID. A.C. and T.R.B.
- 14 collected the samples from ARRL and ACL with clinical data collection coordinated by R.G.,
- 15 K.C.L. and F.L. O.H., A.G.W., J.S. and E.A. collated and linked the case and diagnostic test
- data. A.C. and T.R.B. performed the laboratory work. T.R.B., A.C. and S.A. carried out the
- NGS data analysis. T.R.B. drafted the initial manuscript together with S.A. and inputs from
- A.C. and later versions were based on input and suggestions from all. All authors contributed
- 19 to the final submitted version. All authors have read and agreed to the final version of the
- 20 manuscript.

21

22

12

Additional Information

23 Competing Interests

- The authors declare no conflict of interest. The funders had no role in the design of the study,
- in the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the
- decision to publish the results.

FIGURE LEGENDS

Figure 1. Phylogenetic analysis of the near full-length sequences of SARS-CoV-2.

The nucleotide sequences were aligned and analysed using the Neighbour Joining method based on nucleotide differences and rooted on the WH01_12_26 belonging to lineage B in MEGA 7.0 20 with a bootstrapping of 1000 replicates. The analysis involved 22 SARS-CoV-2 sequences (Table S1), including 6 sequences from this study. Branch lengths are scaled according to the number of nucleotide differences. The sequences from the current study have been labelled with a black triangle (\blacktriangle).

Figure 2. Maximum parsimony phylogenetic network analysis of the near full length sequences of SARS-CoV-2 using Network v5 23 with an epsilon value of 10.

The analysis involved 22 SARS-CoV-2 sequences (Table S1), including 6 sequences from this study. Each unique sequence is represented by a coloured circle showing the identity and frequency in the dataset. Branch length is proportional to the number of nucleotide differences and the position of changed nucleotide is shown in red. The larger circle labelled CBA2_03_24 also includes sequence CBA6_04_07 as these two sequences were identical. Other circles with mixed colour represent two identical sequences.

Table 1. Basic details of 14 samples included in this study. The results of the SARS-COV-2 RT-PCR test (Ct value), the sequence names and GISAID accession numbers are shown. Samples collected from the same individual at different dates are highlighted with same colour.

GCEID Sample ID	Travel History	Clinical Symptoms	Occupation	Sampling date	SARS- COV-2 RT-PCR Test (Ct Value)	Shortened Sequence Name	GISAID Accession
GC-28	Hong Kong	Fever, cough, sore throat, body pains, chest pain, non- productive cough	Non health care worker	28/01/2020	Not Detected	-	-
GC-26	US	Sore throat, dry cough	Non health care worker	7/03/2020	Detected (21)	VIC-CBA4 (CBA4_03_07)	EPI_ISL_430064
GC-13	Europe	Body aches, headaches, dry cough, shortness of breath	Health care worker	23/03/2020	Detected (29)	VIC-CBA1 (CBA1_03_23)	EPI_ISL_420855
GC-11	UK	Cold, sinusitis	Health care worker	24/03/2020	Detected (19)	VIC-CBA2 (CBA2_03_24)	EPI_ISL_420876
GC-12	No travel history	Sore throat, rigor, fever	Health care worker	24/03/2020	Detected (31)	-	Partial sequence
GC-14	UK	Unspecified	Health care worker	28/03/2020	Detected (18)	VIC-CBA3 (CBA3_03_28)	EPI_ISL_420877
GC-17	Canada/US	Sinusitis gradually got worse	Non health care worker	1/04/2020	Detected (33)	-	-
GC-20	UK	Cold, sinusitis	Health care worker	2/04/2020	Detected (31)	-	Partial sequence
GC-21	UK	Shortness of breath, cough, rhinorrhoea and sore throat	Non health care worker	3/04/2020	Detected (31)	-	Partial sequence
GC-22	UK	Cold, sinusitis	Health care worker	3/04/2020	Detected (34) -		-
GC-24	UK	Cold, sinusitis	Health care worker	7/04/2020	Detected (31)	VIC-CBA6 (CBA6_04_07)	EPI_ISL_430066
GC-23	UK	Asymptomatic	Health care worker	8/04/2020	Detected (31)	VIC-CBA5 (CBA5_04_08)	EPI_ISL_430065
GC-25	UK	Sore throat, hoarse voice	Non health care worker	10/04/2020	Detected (19)	-	Partial sequence
GC-51	UK	Asymptomatic	Health care worker	14/04/2020	Detected (31)	-	Partial sequence

Table 2. Change of nucleotides and corresponding amino acids within the Greater Geelong SARS-CoV-2 sequences when compared with WH01_12_26 (GISAID accession: EPI_ISL_406798). Nucleotide changes are shown in bold. UTR: Untranslated Region, ORF: Open Reading Frame, non-structural protein (nsp), S (Region): Surface glycoprotein, N (Region): Nucleocapsid phosphoprotein, N/A: Not applicable.

S. N	Nucleotide Position	Region	Nucleotide						Amino	
			VIC- CBA 1	VIC- CBA 2	VIC- CBA 3	VIC- CBA 4	VIC- CBA 5	VIC- CBA 6	Animo Acid Change	Amino acid type
1	241	5' UTR	Т	Т	Т	С	Т	T	N/A	N/A
2	2416	orf1a (nsp2)	С	T	С	C	С	T	NO	N/A
3	3037	orf1a (nsp3)	Т	Т	Т	С	Т	T	NO	N/A
4	4510	orf1a (nsp3)	G	Т	G	G	G	T	NO	N/A
5	7765	orf1a (nsp3)	С	Т	С	С	С	T	NO	N/A
6	8782	orf1a (nsp4)	С	С	С	Т	С	С	NO	N/A
7	11638	orf1a (nsp6)	T	Т	С	T	С	Т	NO	N/A
8	14408	orf1b (nsp12)	Т	Т	Т	С	Т	Т	P to L	Both Aliphatic
9	17747	orf1b (nsp13)	С	С	С	Т	С	С	P to L	Both Aliphatic
10	17858	orf1b (nsp13)	A	A	A	G	A	A	Y to C	Aromatic to Sulphur Containing
11	18060	orf1b (nsp13)	C	C	С	T	С	C	NO	N/A
12	20578	orf1b (nsp15)	G	Т	G	G	G	T	V to L	Both Aliphatic
13	22326	S	Т	С	Т	С	Т	С	S to F	Hydroxylic to aromatic
14	23403	S	G	G	G	A	G	G	D to G	Acidic to aliphatic
15	24694	S	A	A	A	T	A	A	NO	N/A
16	25563	ORF3a	G	T	G	G	G	T	Q to H	Amidic to Basic
17	27670	ORF7a	G	Т	G	G	G	T	V to F	Aliphatic to Aromatic
18	28144	ORF8	Т	Т	Т	C	Т	Т	L to S	Aliphatic to hydroxylic
19	28881	N	A	G	A	G	A	G	RG to KR	Basic + aliphatic to both basic
20	28882	N	A	G	A	G	A	G		
21	28883	N	С	G	С	G	С	G		
22	29066	N	A	A	A	A	G	A	T to A	Hydroxylic to aliphatic
23	29708	3' UTR	С	С	T	С	Т	С	N/A	N/A



